Predicting worsening visual field via masked dual stage attention recurrent neural network.
Source check: Source checked. Not independent scientific confirmation.
Finding: A masked dual-stage attention recurrent neural network predicted future visual fields in glaucoma from 154,105 examinations, with severity-specific held-out comparisons against observed values.
Technology: A masked dual-stage attention recurrent neural network predicted future visual fields in glaucoma from 154,105 examinations, with severity-specific held-out comparisons against observed values.
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- A masked dual-stage attention recurrent neural network predicted future visual fields in glaucoma from 154,105 examinations, with severity-specific held-out comparisons against observed values.
- Test and result
- Held-out visual-field error metrics were reported across glaucoma severity groups; the retrospective evaluation does not establish prospective clinical benefit or deployment robustness.
- Limitation / still unknown
- The reviewed source does not establish prospective benefit, broad external validity, or replication beyond the reported study.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://www.nature.com/articles/s41598-026-51152-3
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.